Artificial Retina Implant Market Research Report Information by Product (Enzymes, Pharma Products, Bulk Chemicals, and Others), by Application (Bioengineering, Genomics, Vaccine Development, Drug Discovery, Fisheries, Aquaculture, Biofuels, Water Treatment Services, and Others), and by End User (Hospitals, Pharmaceutical Companies, Biotechnology Companies, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) – Industry Forecast till 2032
In 2025, the Artificial Retina Implant Market was estimated to be worth USD 1.51 billion. The Artificial Retina Implant industry is anticipated to experience a compound annual growth rate (CAGR) of 21.22% from USD 1.92 billion in 2026 to USD 7.04 billion by 2032 during the forecast period (2026-2032).
The growing number of startups associated with artificial retina implants and the increasing incidences of age-related macular degeneration (AMD) and retinitis pigmentosa are the factors that are propelling the growth of the global market.
In September 2021, Bionic Vision Technologies, a renowned company in the field of artificial retina technology, announced a significant partnership with Cirtec Medical, a prominent medical technology company based in the United States. The design process will be simplified because of the collaborative effort, which will facilitate joint production for the next iteration of bionic eyes. Bionic Vision Technologies aims to enhance its innovative bionic eye technology to provide a more effective vision solution for individuals with visual impairments by leveraging Cirtec Medical's knowledge base and resources.
Market segment insightsEpiretinal implants, subretinal implants, and suprachoroidal implants comprise the Artificial Retina Market, which is segmented according to product type.
Age-related macular degeneration (AMD) and retinitis pigmentosa comprise the Artificial Retina Market, which is segmented according to its application.
Regional PerspectivesThe market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2025, the North American artificial retina implant market held the largest market share, exceeding 50.12%, because of the Food Drug Administration's (FDA) approval of implant products and the growing prevalence of age-related macular degeneration (AMD). For example, Argus II is a product that has been approved by the FDA and is available in the United States.
During the forecast year of 2025–2026, the artificial retina implant market in Europe is expected to experience substantial growth because of the frequent strategic alliances between market participants in order to meet consumer demand. For example, in July 2022, Pixium Vision (France) announced the successful implantation of the first patient in the Netherlands in the Prima System European pivotal trial PRIMAvera. Pixium Vision has since implanted patients in the UK and Germany and established additional clinical sites.
The geriatric population in the Asia-Pacific region is expected to significantly contribute to the growth of the artificial retina implant market during the forecast period, making it the fastest-growing region. For example, the Asia-Pacific Report on Population Ageing 2022 indicates that there were approximately 670 million individuals aged 60 or older in the Asia-Pacific region in 2022. Additionally, it has been projected that the number of individuals in the Asia-Pacific region will double to approximately 1.3 billion by 2050.
Major PlayersBionic Vision Technologies (US), PIXIUM VISION (France), Optobionics (US), Labtician Ophthalmics, Inc (Canada), Vivani Medical Inc. (US), iBIONICS (Canada), LambdaVision, Inc. (US), AXORUS (France), Sensor-Tech Lab (Russia), and Nanovision (US) are among the key companies in the Artificial Retina Implant Market.